Hematopoietic Biorepository and Cellular Therapy Facility Work Policy (Effective March 18, 2020)

Policy Statement: We will no longer be able to procure and distribute fresh normal donor blood and bone marrow samples due to the current COVID-19 situation. We will continue with all other services.

Revisions to Operating Protocol: Our new procedures will minimize face to face interactions and utilize virtual communications if possible. To implement necessary social distancing recommendations and avoid in-person interactions, we will communicate primarily by phone and email with users when possible. In addition, biorepository samples will be provided by leaving them at a specified time in a box outside the door of our facility.

Workflow: The general workflow of our facility will be adjusted to minimize the presence of multiple facility personnel working in the lab at the same time. We do not anticipate that this will have a significant impact on our facility.

Hematopoietic Biorepository and Cellular Therapy


The Hematopoietic Biorepository and Cellular Therapy Shared Resource (SR) serves as a resource for procurement, processing, storage, banking, analysis, and distribution of cells derived from clinical-grade production, human blood, bone marrow, and umbilical cords.

The SR is comprised of two components:

  1. A human hematopoietic biorepository and support services to facilitate basic hematopoietic research

  2. A clinical Cellular Therapy Lab that manufactures clinical-grade cell products for investigational and standard of care therapies

Facility Objectives

  • To procure, de-identify, process and distribute human blood, umbilical cord blood, and bone marrow cells from healthy volunteers and patients to investigators
  • To maintain a biorepository of collected samples
  • To perform and assist investigators with standard assays to evaluate hematopoiesis and hematopoietic and mesenchymal stem cells
  • To support cell therapy-based clinical trials from the proof of concept stage throughout the clinical trial

List of Services

  1. Procurement and distribution of human hematopoietic cells:
    • The SR maintains an active IRB protocol to enable the recruitment of donors and procurement and distribution of de-identified blood and bone marrow samples to research investigators. We also maintain a Biorepository to supply investigators with cryopreserved samples. Sample types obtained include:
      • Normal donor blood
      • Normal donor bone marrow aspirate and/or biopsy samples
      • Umbilical cord blood
      • Peripheral mobilized hematopoietic progenitor cells
      • Bone marrow mesenchymal stem cells
      • Blood and/or bone marrow from patients with a wide variety of hematologic diseases including AML, ALL, CML, CLL, multiple myeloma, and anemia
  2. Processing and analysis of hematopoietic cells:
    • The SR assists investigators with the processing and analysis of hematopoietic cells using a variety of methodologies. Examples of some of these procedures include:
      • Separation of mononuclear cells by density gradient (Ficoll-Hypaque or Percoll)
      • Cell enrichment using CliniMACS magnetic bead separation (ex. CD34+ cell isolation)
      • Isolation and expansion of mesenchymal stem cells
      • Maintenance of specialized equipment available for research use including a hematology analyzer to perform CBCs
      • Performance of colony forming unit assays (CFU) on blood and bone marrow products
      • Separation of plasma/serum
  3. Production of clinical grade cellular therapy products
    • Isolation of specific cell subsets (CD34, CD3, CD14, etc.)
    • Expansion of various cell types upon request
    • Ex-vivo lentiviral gene transfer
  4. Support capabilities to transition preclinical studies into clinical trials
    • Assistance in the design and preparation of cells for Good Laboratory Practices (GLP) safety studies
    • Investigational New Drug Application (IND) preparation
    • Sourcing of clinical grade supplies and reagents
    • Scale up from research to clinical operations, including preparation of investigational clinical therapy grade cellular products
    • GMP training to lab investigators


Hemavet Hematology Analyzer
Guava Cytometer
Biorad QPCR machine
ISO 7 cleanroom suites (6) each with incubators, centrifuge, biosafety cabinet, microscope, refrigerator
GMP-trained lab personnel
COBE closed system cell washer
Rate controlled freezing chamber
Clinical grade Cytokine stocks: Interleukins 3 and 6, stem cell factor and Flt-3 ligand, thrombopoietin
VarioMACS columns/antibody cocktails for routine separation of CD34+ cells and other cell subsets
Shandon Cytospin


Remember to acknowledge the valuable services provided by Cancer Center Shared Resources in your research papers and publications: 
"This research was supported by the Hematopoietic Biorepository and Cellular Therapy Shared Resource of the Case Comprehensive Cancer Center (P30CA043703)."

Contact for Information

Location Wolstein Research Building 6-303
Core Contact Basabi Maitra
Scientific Director David N. Wald, MD, PhD
Operations Director Jane Reese Koç, MBA, MT